DNLI

Denali Therapeutics Inc. (DNLI) | Rumor.io

Denali Therapeutics

DNLI

Attention (50-day avg)0%

Attention rank (50-day avg)#2,139

Bullish sentiment (50-day avg)100%

Price to earnings ratio-7.07

Market capitalization3.4B

Earnings per share-2.84

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-512.5M

Social

What share of all stock conversation is about DNLI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Jun 27

Denali Therapeutics Inc. ($DNLI) mentioned as a stock that has seen a significant gain of 34% in a month.
The stock was mentioned alongside $ILMN, suggesting a possible comparison or correlation between the two.
No specific details about the company's performance or news were provided.

Generated by AI

Sentiment

Of the messages about DNLI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	81.19% -4.38
Bearish	—	—	0% 0	18.81% +4.38

Mar 25

Denali Therapeutics Inc. (DNLI) stock jumps on FDA approval of its lead asset, Avlayah, developed with RPRX for Hunter syndrome.
DNLI's approval has a de-risking effect, potentially pushing the price to $100-200 million plus cash, driven by its low float and pricing of the drug's possible revenue.
DNLI's recent FDA approval has triggered a breakout, clearing the nearby daily pivot, with no resistance thereafter, and is expected to continue its upward trend.

Generated by AI

Topics

Of the messages about DNLI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	90.11%
Analysts	—	—	100%	3.38%
Controversies	—	—	0%	0.29%
Earnings	—	—	0%	0%
Macro	—	—	0%	1.71%
Technical Analysis	—	—	0%	4.5%

Earnings· Aug 9

Denali Therapeutics Inc. (DNLI) misses earnings per share (EPS) estimates by $0.39.
DNLI also misses revenue expectations.
DNLI's earnings miss is attributed to a loss of $0.39.

Announcements· Mar 25

The FDA has approved Denali Therapeutics' (DNLI) AVLAYAH (tividenofusp alfa-eknm) for the treatment of Hunter Syndrome (MPS II), a rare lysosomal storage disease.
This approval marks the first new treatment option in nearly 20 years for families living with Hunter Syndrome and is considered a significant biotech catalyst for 2026.
The FDA's approval of AVLAYAH has been seen as a positive regulatory event, indicating flexibility in the agency's approach to rare disease treatments and a major hurdle cleared for Denali's rare-disease strategy.

Generated by AI

Community

Of the messages about DNLI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	13.51%	60.83%	36.9%
Newcomers	100%	86.49%	39.17%	63.1%

Regulars· Mar 25

The FDA has approved Denali's AVLAYAH for the treatment of Hunter syndrome, marking the first new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage disease.
The approval was unexpected, as the company did not request a Priority Review (PRV) with the application submission, and the FDA's flexibility in granting the PRV is surprising given the legislation wording.
Denali's AVLAYAH has gained FDA accelerated approval, making it the first brain-penetrating enzyme therapy for Hunter syndrome (MPS II) in nearly 20 years, and could potentially reshape neurodegenerative therapies.

Newcomers· Jun 27

The newcomer is sharing a friend's success with a 34% return in a month by investing in $DNLI.
The friend's investment portfolio includes $ILMN and $DNLI.
The newcomer is recommending investment in $DNLI based on their friend's results.

Generated by AI

News

Denali Therapeutics at Morgan Stanley conference: launch momentum builds

15d agoInvesting.com

Denali Therapeutics director sells $261,928 in stock

25d agoInvesting.com

B. Riley Adjusts Denali Therapeutics Price Target to $35 From $30, Maintains Buy Rating

Denali Therapeutics (DNLI) has an average rating of buy and mean price target of $34.88, according t

1mo agofinance.yahoo.com

FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome

1mo agoReuters

DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?

Denali's Avlayah launch drives strong uptake and a 33.1% three-month stock gain, but regulatory and pipeline risks remain.

1mo agoYahoo Finance

Denali Therapeutics: Bullish On AVLAYAH And Their Prospects (NASDAQ:DNLI)

1mo agoSeeking Alpha

Also Discussed

Investors talking about DNLI also mention

#	Name	Attention
1	Alector Inc.ALEC	0%new
2	MeiraGTx Holdings plcMGTX	0%new
3	Regenxbio Inc.RGNX	0%+0
4	Sphere Entertainment Co. Class A Common StockSPHR	0%+0
5	Mirum Pharmaceuticals, Inc.MIRM	0%0
6	Revolution Medicines, Inc.RVMD	0.01%-0.01
7	UFP Technologies Inc.UFPT	0%0
8	Nurix Therapeutics, Inc.NRIX	0%new
9	BioAge Labs, Inc.BIOA	0.01%+0
10	Standex International CorporationSXI	0%new

Denali Therapeutics Inc.

Healthcare
Biotechnology

Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing medicines for serious neurodegenerative and lysosomal storage diseases. Denali Therapeutics advances a portfolio of therapeutic programs aimed at conditions such as Alzheimer's disease, Parkinson's disease, and other rare neurological disorders. The company’s approach centers on delivering biologic and genetic medicines across the blood-brain barrier through its proprietary TransportVehicle platform, which is designed to improve access to hard-to-reach tissues in the central nervous system. Denali Therapeutics also works on product candidates across enzyme, oligonucleotide, and antibody-based programs, supporting a broader pipeline that targets both brain and body diseases. Headquartered in South San Francisco, California, Denali Therapeutics operates within the biotechnology sector and plays a role in the development of next-generation therapies for complex, high-unmet-need conditions.

Website

Location

161 Oyster Point Boulevard

South San Francisco, CA, 94080

United States

Social

What share of all stock conversation is about DNLI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Jun 27

Denali Therapeutics Inc. ($DNLI) mentioned as a stock that has seen a significant gain of 34% in a month.
The stock was mentioned alongside $ILMN, suggesting a possible comparison or correlation between the two.
No specific details about the company's performance or news were provided.

Generated by AI

Sentiment

Of the messages about DNLI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	81.19% -4.38
Bearish	—	—	0% 0	18.81% +4.38

Mar 25

Denali Therapeutics Inc. (DNLI) stock jumps on FDA approval of its lead asset, Avlayah, developed with RPRX for Hunter syndrome.
DNLI's approval has a de-risking effect, potentially pushing the price to $100-200 million plus cash, driven by its low float and pricing of the drug's possible revenue.
DNLI's recent FDA approval has triggered a breakout, clearing the nearby daily pivot, with no resistance thereafter, and is expected to continue its upward trend.

Generated by AI

Topics

Of the messages about DNLI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	90.11%
Analysts	—	—	100%	3.38%
Controversies	—	—	0%	0.29%
Earnings	—	—	0%	0%
Macro	—	—	0%	1.71%
Technical Analysis	—	—	0%	4.5%

Earnings· Aug 9

Denali Therapeutics Inc. (DNLI) misses earnings per share (EPS) estimates by $0.39.
DNLI also misses revenue expectations.
DNLI's earnings miss is attributed to a loss of $0.39.

Announcements· Mar 25

The FDA has approved Denali Therapeutics' (DNLI) AVLAYAH (tividenofusp alfa-eknm) for the treatment of Hunter Syndrome (MPS II), a rare lysosomal storage disease.
This approval marks the first new treatment option in nearly 20 years for families living with Hunter Syndrome and is considered a significant biotech catalyst for 2026.
The FDA's approval of AVLAYAH has been seen as a positive regulatory event, indicating flexibility in the agency's approach to rare disease treatments and a major hurdle cleared for Denali's rare-disease strategy.

Generated by AI

Community

Of the messages about DNLI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	13.51%	60.83%	36.9%
Newcomers	100%	86.49%	39.17%	63.1%

Regulars· Mar 25

The FDA has approved Denali's AVLAYAH for the treatment of Hunter syndrome, marking the first new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage disease.
The approval was unexpected, as the company did not request a Priority Review (PRV) with the application submission, and the FDA's flexibility in granting the PRV is surprising given the legislation wording.
Denali's AVLAYAH has gained FDA accelerated approval, making it the first brain-penetrating enzyme therapy for Hunter syndrome (MPS II) in nearly 20 years, and could potentially reshape neurodegenerative therapies.

Newcomers· Jun 27

The newcomer is sharing a friend's success with a 34% return in a month by investing in $DNLI.
The friend's investment portfolio includes $ILMN and $DNLI.
The newcomer is recommending investment in $DNLI based on their friend's results.

Generated by AI

Denali Therapeutics

Social

Jun 27

Mar 25

Earnings· Aug 9

Announcements· Mar 25

Regulars· Mar 25

Newcomers· Jun 27

Denali Therapeutics at Morgan Stanley conference: launch momentum builds

Denali Therapeutics director sells $261,928 in stock

B. Riley Adjusts Denali Therapeutics Price Target to $35 From $30, Maintains Buy Rating

FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome

DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?

Denali Therapeutics: Bullish On AVLAYAH And Their Prospects (NASDAQ:DNLI)

Also Discussed

Denali Therapeutics Inc.

Company Information

Location

Denali Therapeutics at Morgan Stanley conference: launch momentum builds

Denali Therapeutics director sells $261,928 in stock

B. Riley Adjusts Denali Therapeutics Price Target to $35 From $30, Maintains Buy Rating

FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome

DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?

Denali Therapeutics: Bullish On AVLAYAH And Their Prospects (NASDAQ:DNLI)

Also Discussed

Social

Jun 27

Mar 25

Earnings· Aug 9

Announcements· Mar 25

Regulars· Mar 25

Newcomers· Jun 27